Treatment challenges in patients with co-infection of drug resistant tuberculosis and human imunodeficiency virus in south east Asia region - a literature review

Mansuri, Fahad (2013) Treatment challenges in patients with co-infection of drug resistant tuberculosis and human imunodeficiency virus in south east Asia region - a literature review. Master Essay, University of Pittsburgh.

	Microsoft Word Submitted Version Available under License : See the attached license file. Download (460kB)
	Plain Text (licence) Available under License : See the attached license file. Download (1kB)

Abstract

The South East Asia region of WHO alone accounts for 60% of all Tuberculosis cases in the world. It also has second largest number of people infected with HIV. The region has largest number of notified MDR-TB cases and an even larger population harboring drug resistant tuberculosis yet to be diagnosed. Most of the member countries in the South East Asia region are developing countries. The convergence of dual epidemic of HIV and MDR-TB can lead to a whole new epidemic. The issues with drug resistant TB and HIV are that little or nothing is known about effective diagnosis, treatment and prevention of co-infection. The public health significance of co-infection is even higher as the treatment of the co-infection is very difficult long and not well tolerated. The co-infection in absence of treatment is almost always fatal. Little or nothing is known about the appropriate regimen to treat the co-infection. The treatment regimens that are currently recommended by WHO are mostly based on small cohort studies. The interaction of second-line anti TB drugs and anti-retroviral therapy at population level is unknown. The review is aimed to describe the burden of drug resistant TB and HIV and also the research on the treatment issues with treatment of the co-infection in the South East Asia region. The results obtained from review show that there is no data on incidence on prevalence of HIV and drug resistant TB at population level. The data is available from few scattered studies and none of the national programs collect data on drug resistant TB and HIV co-infection. This limits our understanding of the real magnitude of the issue in the region. It is also observed that there is hardly any data or research that is done to better understand the treatment issues with co-infection in the region. Thus due to limited amount of data no certain conclusions can be made at this point of time. It is certainly though that the issue of HIV and drug resistant TB needs to be at the priority list for national programs in the South East Asia region.

---

Share

Citation/Export:	Select format... Citation - Text Citation - HTML Endnote BibTex Dublin Core OpenURL MARC (ISO 2709) METS MODS EP3 XML Reference Manager Refer
Social Networking:	Share |

---

Details

Item Type:	Other Thesis, Dissertation, or Long Paper (Master Essay)
Status:	Unpublished
Creators/Authors:	Creators Email Pitt Username ORCID Mansuri, Fahad
Contributors:	Contribution Contributors Name Email Pitt Username ORCID Committee Chair Songer, Thomas tjs@pitt.edu TJS UNSPECIFIED Committee Member Wang, Tianyi tywang@pitt.edu TYWANG UNSPECIFIED
Date:	22 April 2013
Date Type:	Publication
Defense Date:	April 2013
Access Restriction:	No restriction; Release the ETD for access worldwide immediately.
Publisher:	University of Pittsburgh
Institution:	University of Pittsburgh
Schools and Programs:	School of Public Health > Epidemiology
Degree:	MPH - Master of Public Health
Thesis Type:	Master Essay
Refereed:	Yes
Uncontrolled Keywords:	Tuberculosis, HIV, drug, resistant, Tuberculosis, epidemiology, and, treatment
Date Deposited:	06 May 2015 22:50
Last Modified:	30 Mar 2022 11:57
URI:	http://d-scholarship.pitt.edu/id/eprint/18610

---

Metrics

Monthly Views for the past 3 years

Plum Analytics

---

Actions (login required)

View Item